Inside 2025’s Biggest Life Science VC Fundraises: $5.7B and Counting

By BioBuzz Media · · 8 min read
Inside 2025’s Biggest Life Science VC Fundraises: $5.7B and Counting

By mid-2025, the biotech venture landscape is defined by paradox. Public markets remain largely unreceptive — IPO windows opening only a crack, secondary offerings punishingly selective — yet venture investors continue to amass billions in fresh dry powder. The result is a two-speed capital market: cash-hungry startups struggling to extend runway while established firms with proven track records are raising some of the largest funds in their histories.

The numbers tell the story. Private biotech financings in the first half of 2025 are down more than 20% compared to the same period in 2024, according to PitchBook, with median deal sizes contracting across Series A and B. But fundraising by venture firms is moving in the opposite direction, as limited partners — from pension plans to sovereign wealth funds — double down on seasoned managers who can source, build, and exit life science companies even in lean times.

At the same time, a shift in strategy is becoming visible. Traditional billion-dollar therapeutics pools remain the cornerstone, but capital is also flowing into specialist funds: dementia-focused vehicles, royalty-and-credit hybrids, industrial bioeconomy plays, and regionally targeted efforts from the Nordics to North Carolina. The throughline is clear: institutional investors believe biology remains one of the defining growth engines of this decade, but they want their money in the hands of VCs with deep scientific expertise, strong syndicate networks, and demonstrable exits.

Here’s a definitive look at the headline biotech and life-science funds raised in 2025 (through August) — who raised them, what they target, and why they matter.

2025’s Major Biotech and Life Science Fund Closes

Frazier Life Sciences XII — $1.3 billion (July 31, 2025)
Frazier’s twelfth life sciences fund is its largest to date, aimed squarely at company creation and early-stage private biopharmaceuticals. Known for building newcos from scratch — often in stealth until a Series A syndicate is ready — Frazier’s heft underscores LP confidence in its formation-first model at a time when capital efficiency is paramount.

Omega Funds VIII — $647 million (July 21, 2025)
Omega’s eighth flagship vehicle will back innovative life-science platforms and therapeutics tackling areas of high unmet need. With a transatlantic footprint and a reputation for rolling up its sleeves in company building, Omega remains one of the few VCs able to pull off mid-market raises in a tough climate.

Curie.Bio Seed Fund II — $340 million (January 29, 2025)
Founded by former Flagship and Third Rock operators, Curie.Bio has quickly carved out a reputation as a founder-friendly accelerator for biotech entrepreneurs. Its second seed fund, at $340 million, will significantly increase the pace of new company launches, with a model built on heavy operational support and an accelerator-style infrastructure for seed-stage science.

Catalio Capital Management — Nexus Fund IV, >$400 million (July 1, 2025)
Baltimore-born Catalio raised more than $400 million for its fourth Nexus fund, cementing its status as a leading mid-market life-sciences investor. Catalio’s thesis blends venture with deep partnerships in academia, backing spinouts and repeat founders across therapeutics, devices, diagnostics, and enabling technologies. Its rise from regional player to national powerhouse highlights the growing decentralization of biotech venture capital beyond Boston and the Bay Area.

SV Health Investors — Dementia Discovery Fund 2 (DDF-2), $269 million (May 20, 2025)
DDF remains the world’s largest specialist VC fund dedicated to dementia, and its second vintage attracted a unique mix of pharmaceutical LPs and mission-driven investors. In a field where big pharma pipelines have been decimated by late-stage failures, DDF-2 represents one of the few concentrated venture bets on solving neurodegeneration.

Hatteras Venture Partners VII & Opportunity Fund I — >$200 million combined (August 13, 2025)
The Research Triangle stalwart doubled down on early-stage life sciences with its seventh flagship, while launching an Opportunity Fund to provide scale-up capital for breakout portfolio companies. For North Carolina’s growing biotech ecosystem, Hatteras’ dual-fund structure ensures local startups can access both seed and growth capital without leaving the state.

HealthCap IX — (final close August 22, 2025)
One of Europe’s longest-running life-science VCs, HealthCap secured new commitments from Novo Holdings and Denmark’s EIFO, and will expand operations into Copenhagen. The fund continues to focus on early-stage therapeutics, especially in the Nordics, cementing Northern Europe’s position as a biotech hub with global reach.

AN Venture Partners I — $200 million (July 2, 2025)
A transpacific newcomer, AN Venture Partners bridges Japanese innovation with U.S. company formation. With offices in Tokyo and San Francisco, the fund will back biotech startups across multiple stages, with an emphasis on cross-border translational opportunities.

Brandon Capital Fund Six — A$439 million (July 24, 2025)
Australia’s largest life-sciences investor closed its sixth fund at A$439 million, a sizable war chest for a region historically undercapitalized relative to its scientific output. The fund will continue building companies from university and research-institute pipelines across Australia and New Zealand.

Forbion BioEconomy Fund I — €164.5 million (January 27, 2025)
Not therapeutics, but adjacent: Forbion launched its first bioeconomy-focused vehicle to back industrial biotech companies developing decarbonization technologies for chemicals, fuels, and materials. It’s a recognition that life-science venture is increasingly spilling into climate and sustainability domains.

Sofinnova Partners — Biovelocita II (€165 million, March 18, 2025); €1.2 billion across platform (March 4, 2025)
The Paris-based VC raised €1.2 billion across multiple strategies over the past year, including Biovelocita II, a €165 million acceleration fund supporting high-potential European therapeutic startups. Sofinnova’s model emphasizes acceleration and operational lift for founders in Europe’s still-fragmented biotech ecosystem.

OrbiMed Royalty & Credit Opportunities Fund V — $1.86 billion (August 4, 2025)
The largest fund raised this year by any healthcare investor, OrbiMed’s fifth royalty and credit fund isn’t equity venture per se, but its impact on the sector is enormous. Offering non-dilutive financing through royalties and credit facilities, the fund provides clinical-stage companies with alternatives to dilutive equity raises — a critical lifeline in today’s tough public markets.

Lilly + Andreessen Horowitz Bio & Health — Lilly Digital Medicine Fund, $500 million (March 2025)
In one of the year’s most intriguing corporate-VC hybrids, Eli Lilly partnered with a16z Bio & Health on a $500 million digital medicine fund. The vehicle will back digital therapeutics and metabolic-health innovations — a recognition that biology, software, and chronic-disease management are converging rapidly.

THENA Capital Fund I — £27 million first close (March 21, 2025; target £50 million)
UK-based THENA Capital is a medtech specialist, focusing on early-stage device and digital health companies with a women’s-health emphasis. Its cornerstone LP is the British Business Bank, part of a push to ensure UK-born startups don’t need to decamp to Boston or the Bay Area to scale.

What’s Happening in the Hubs

The capital raised in 2025 is a good bell-weather for investment to come, but so far 2025 has continued to show that much of the “dry powder” is still sitting on the sidelines.

BioBuzz just released our 2025 Greater Philadelphia Investment Report which gives you a deeper dive into the major funding milestones to groundbreaking innovations. This report reveals the capital, investors, and visionary founders behind Philadelphia’s most successful life science companies. Download your copy today.

From the report we learned that the Greater Philadelphia Life Sciences sector raised $950 million in the first half of 2025 across 28 deals , with venture capital accounting for $488 million—almost half of the total investments across 22 deals. Series A and B rounds led with a combined $195 million, underscoring continued confidence in early- and mid-stage companies, even as investors shifted toward fewer, higher-value transactions. Interestingly, venture investment in 1H 2025 is at 50% of the total venture funding raised in 2024, signaling that venture may not be the primary driver in this off-year.

Meanwhile, in North Carolina, long home to Hatteras Venture Partners, capital has translated directly into durable biotech franchises. Hatteras was an early investor in StrideBio, a Durham-based gene therapy company where it continues to hold a board seat, and it led the seed round for G1 Therapeutics, one of the Triangle’s better-known public biopharma companies . These case studies illustrate how headline fundraises ultimately ripple down into regional ecosystems—turning capital commitments into jobs, new science, and tangible growth across the U.S. biotech map.

Key Takeaways

Taken together, 2025’s fundraises show how life-science venture is adapting to a new equilibrium:

  • Scale at the top, focus at the edges. Mega-funds like Frazier’s $1.3 billion and OrbiMed’s $1.86 billion ensure late-stage and company-creation capital remains available, but specialist funds like DDF-2 and Forbion’s BioEconomy I signal growing appetite for targeted bets.
  • Geographic diversification. From Catalio in New York to Brandon Capital in Australia, HealthCap in Scandinavia, and AN Venture bridging Tokyo and SF, biotech venture is decentralizing — broadening the map of where startups can raise serious capital.
  • Alternative financing ascendant. OrbiMed’s royalty and credit fund highlights a structural shift: as equity markets remain costly, non-dilutive capital is no longer niche but a mainstream pillar of biotech financing.
  • Pharma’s deeper involvement. Lilly’s digital medicine partnership with a16z signals pharma is willing to act like a VC — not only acquiring but co-creating new business models around chronic diseases and digital therapeutics.

Biotech venture is in flux, but it’s not retreating. Investors are writing fewer checks into startups, but they’re raising bigger funds than ever, consolidating power into the hands of proven managers while experimenting at the edges with specialist strategies and corporate-VC hybrids.

For founders, the message is sobering but clarifying: the capital is out there, but you need to match your science with the right fund thesis. A dementia startup? DDF-2 might be your best route. A metabolic digital health platform? Lilly’s new fund is built for you. A Baltimore spinout? Catalio has dry powder and local know-how.

2025 may be remembered as the year biotech venture bifurcated — where the billion-dollar franchises got bigger, the niche specialists doubled down, and the industry’s capital stack quietly rewired itself for a leaner, more selective, but still ambitious decade ahead.

Direct Links to Fund Announcements

Here are links to all of the major funds that we found this year so that you can do your diligence and get their attention for your fundraising goals.

Tagged:
BM

BioBuzz Media

BioBuzz is a life science media and community organization connecting professionals, companies, and organizations across the Mid-Atlantic region.

Upcoming Events

Project Management Professional (PMP) Boot Camp Training –Virtual Course

Outsourced Pharma Capabilities Update – Fill/Finish

Outsourced Pharma Capabilities Update – Small Molecule Drug Product

Outsourced Pharma Capabilities Update – Cell & Gene

Webinar: Engineering Microbes and Microbial Communities for Sustainable Bioproduction
View All Events →

Related Articles